Literature DB >> 29467480

Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles.

Simon Andreasen1,2, Qihua Tan3, Tina Klitmøller Agander4, Petr Steiner5,6, Kristine Bjørndal7, Estrid Høgdall8, Stine Rosenkilde Larsen9, Daiva Erentaite10, Caroline Holkmann Olsen11, Benedicte Parm Ulhøi12, Sarah Linéa von Holstein13,14, Irene Wessel15, Steffen Heegaard4,13, Preben Homøe16.   

Abstract

Adenoid cystic carcinoma is among the most frequent malignancies in the salivary and lacrimal glands and has a grave prognosis characterized by frequent local recurrences, distant metastases, and tumor-related mortality. Conversely, adenoid cystic carcinoma of the breast is a rare type of triple-negative (estrogen and progesterone receptor, HER2) and basal-like carcinoma, which in contrast to other triple-negative and basal-like breast carcinomas has a very favorable prognosis. Irrespective of site, adenoid cystic carcinoma is characterized by gene fusions involving MYB, MYBL1, and NFIB, and the reason for the different clinical outcomes is unknown. In order to identify the molecular mechanisms underlying the discrepancy in clinical outcome, we characterized the phenotypic profiles, pattern of gene rearrangements, and global microRNA expression profiles of 64 salivary gland, 9 lacrimal gland, and 11 breast adenoid cystic carcinomas. All breast and lacrimal gland adenoid cystic carcinomas had triple-negative and basal-like phenotypes, while salivary gland tumors were indeterminate in 13% of cases. Aberrations in MYB and/or NFIB were found in the majority of cases in all three locations, whereas MYBL1 involvement was restricted to tumors in the salivary gland. Global microRNA expression profiling separated salivary and lacrimal gland adenoid cystic carcinoma from their respective normal glands but could not distinguish normal breast adenoid cystic carcinoma from normal breast tissue. Hierarchical clustering separated adenoid cystic carcinomas of salivary gland origin from those of the breast and placed lacrimal gland carcinomas in between these. Functional annotation of the microRNAs differentially expressed between salivary gland and breast adenoid cystic carcinoma showed these as regulating genes involved in metabolism, signal transduction, and genes involved in other cancers. In conclusion, microRNA dysregulation is the first class of molecules separating adenoid cystic carcinoma according to the site of origin. This highlights a novel venue for exploring the biology of adenoid cystic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467480     DOI: 10.1038/s41379-018-0005-y

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.

Authors:  Yue Jiang; Ruli Gao; Chunxia Cao; Lauren Forbes; Jianping Li; Shelby Freeberg; Kristianna M Fredenburg; Jeb M Justice; Natalie L Silver; Lizi Wu; Sushama Varma; Robert West; Jonathan D Licht; Maria Zajac-Kaye; Alex Kentsis; Frederic J Kaye
Journal:  Oral Oncol       Date:  2019-10-10       Impact factor: 5.337

2.  The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland.

Authors:  Simon Andreasen; Sushama Varma; Nicholas Barasch; Lester D R Thompson; Markku Miettinen; Lisa Rooper; Edward B Stelow; Tina K Agander; Raja R Seethala; Simion I Chiosea; Preben Homøe; Irene Wessel; Stine R Larsen; Daiva Erentaite; Justin A Bishop; Benedicte P Ulhøi; Katalin Kiss; Linea C Melchior; Jonathan R Pollack; Robert B West
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

Review 3.  Pathogenesis of Triple-Negative Breast Cancer.

Authors:  Fatemeh Derakhshan; Jorge S Reis-Filho
Journal:  Annu Rev Pathol       Date:  2022-01-24       Impact factor: 32.350

4.  The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.

Authors:  Christopher J Schwartz; Edi Brogi; Antonio Marra; Arnaud F Da Cruz Paula; Gouri J Nanjangud; Edaise M da Silva; Sujata Patil; Shreena Shah; Katia Ventura; Pedram Razavi; Larry Norton; Timothy D'alfonso; Britta Weigelt; Fresia Pareja; Jorge S Reis-Filho; Hannah Y Wen
Journal:  Mod Pathol       Date:  2021-10-01       Impact factor: 8.209

Review 5.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

6.  Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.

Authors:  Petr Šteiner; Simon Andreasen; Petr Grossmann; Lukáš Hauer; Tomáš Vaněček; Markéta Miesbauerová; Thalita Santana; Katalin Kiss; David Slouka; Alena Skálová
Journal:  Virchows Arch       Date:  2018-04-04       Impact factor: 4.064

7.  A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate.

Authors:  Lin He; Christopher Metter; Vitaly Margulis; Payal Kapur
Journal:  Case Rep Pathol       Date:  2021-05-04

8.  MLMDA: a machine learning approach to predict and validate MicroRNA-disease associations by integrating of heterogenous information sources.

Authors:  Kai Zheng; Zhu-Hong You; Lei Wang; Yong Zhou; Li-Ping Li; Zheng-Wei Li
Journal:  J Transl Med       Date:  2019-08-08       Impact factor: 5.531

Review 9.  Extracellular Vesicles: New Endogenous Shuttles for miRNAs in Cancer Diagnosis and Therapy?

Authors:  Stefano Martellucci; Nicola Salvatore Orefice; Adriano Angelucci; Amalia Luce; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 5.923

10.  HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Kristian Egebjerg; Cecilie Dupont Harwood; Nina Claire Woller; Claus Andrup Kristensen; Morten Mau-Sørensen
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.